The Nasdaq listing issue is very curious.

Is the intent to list and allow for greater liquidity and have the stock above $5, or is there a dual purpose that being to increase liquidity and raise capital to fund the burn for the next several months and take out the remaining Third Eye loan?

If that/this was the case, it would have seemed to have made more sense to have done done this in Oct or Nov so RVX would not be hand to private placement? However, without topline results, the appetite would likely not be large for a listing or equity raise and the timing would likely have been too tight.

If the plan is to wait for topline results (that are positive) before listing, hopefully there would be no consolidation necessary and an equity raise would be strategic to cover anticipated costs for say the next year (the main reason for this would be to show Big Pharma we are not financially weak and/or to allow time to provide the detailed analysis to prove the stock is worth more and has mutiple applications) ?

The recent Makalu reported suggested they expect RVX to be bought out shortly after the topline results if positive with a $30 US valuation. If the company thought this realistic, why list on the Nasdaq?

I assume management has a plan, it will be interesting to see it unfold. Hopefully it is for the shareholders betterment and not Wall Street’s.